Abstract ↗AI summary
The abstract is read at the publisher; the summary is JClub's.
Cytokine-enhanced CAR T-cell designs—starting with IL-12 and expanding through common g-chain cytokines and IL-18—aim to improve expansion, persistence, and function while managing toxicity risks.
- Why it matters: Durable efficacy in B-cell malignancies is limited by insufficient CAR T expansion and persistence, progressive T-cell dysfunction, and immunosuppressive tumor microenvironments. Cytokines regulate T-cell fitness and immune interactions, motivating their direct incorporation into engineered therapies.
- What they did: The work traces development from pioneering IL-12 studies to clinical translation using common g-chain cytokines, especially IL-7, IL-15, and IL-21, plus IL-18. It also highlights newer approaches such as inducible circuits, synthetic cytokine receptors, unconventional cytokines, and combinations of complementary signals.
- The result: IL-12 showed local inflammatory potency and mobilization of endogenous immunity but also systemic inflammatory toxicity risk, while IL-18 has shown encouraging clinical activity in hematologic malignancies. These strategies suggest that disease-specific cytokine choice and precise spatial/temporal control are critical to balance efficacy against toxicity.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.
Free. We’ll email you when a new paper cites this one or any other paper you follow on JClub — at most one email a day. Every email has a one-tap unsubscribe.